多发性骨髓瘤(MM)是一种恶性浆细胞疾病,常伴有多发性溶骨性损害、高钙血症、贫血、肾脏损害。从最初的马法兰到自体移植及硼替佐米、来那度胺的应用,骨髓瘤患者的生存状况有了明显改善,但与此同时远期并发症如第二肿瘤的发生也越来越引起关注。我院2007年1月―2014年10月收治MM患者91例,其中4例继发第二肿瘤,分析患者 Multiple myeloma (MM) is a malignant plasma cell disease, often accompanied by multiple osteolytic lesions, hypercalcemia, anemia, and kidney damage. From the initial melphalan to autografts and bortezomib, the benefit of lenalidomide was a significant improvement in the survival of patients with myeloma, but at the same time, the incidence of long-term complications, such as the second tumor, was also drawing more and more attention . In our hospital from January 2007 to October 2014, MM patients were treated in 91 cases, of which 4 cases of second tumor secondary to analysis of patients